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Summary
OBJECTIVES: To assess the use of the Clinical EULAR
Sjögren’s Syndrome Disease Activity Index (ClinESSDAI),
a version of the ESSDAI without the biological domain,
for assessing potential eligibility and outcomes for clinical
trials in patients with primary Sjögren’s syndrome (pSS),
according to the new ACR-EULAR classification criteria,
from the UK Primary Sjögren’s Syndrome Registry
(UKPSSR).
METHODS: A total of 665 patients from the UKPSSR co-
hort were analysed at their time of inclusion in the reg-
istry. ESSDAI and ClinESSDAI were calculated for each
patient.
RESULTS: For different disease activity index cut-off val-
ues, more potentially eligible participants were found when
ClinESSDAI was used than with ESSDAI. The distribution
of patients according to defined disease activity levels did
not differ statistically (chi2 p = 0.57) between ESSDAI and
ClinESSDAI for moderate disease activity (score ≥5 and
<14; ESSDAI 36.4%; ClinESSDA 36.5%) or high disease
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activity (score ≥14; ESSDAI 5.4%; ClinESSDAI 6.8%). We
did not find significant differences between the indexes in
terms of activity levels for individual domains, with the ex-
ception of the articular domain. We found a good level of
agreement between both indexes, and a positive corre-
lation between lymphadenopathy and glandular domains
with the use of either index and with different cut-off val-
ues. With the use of ClinESSDAI, the minimal clinically
important improvement value was more often achievable
with a one grade improvement of a single domain than
with ESSDAI. We observed similar results when using the
new ACR-EULAR classification criteria or the previous-
ly used American-European Consensus Group (AECG)
classification criteria for pSS.
CONCLUSIONS: In the UKPSSR population, the use of
ClinESSDAI instead of ESSDAI did not lead to significant
changes in score distribution, potential eligibility or out-
come measurement in trials, or in routine care when im-
munological tests are not available. These results need to
be confirmed in other cohorts and with longitudinal data.
Key words: Sjögren’s, clinical trial, eligibility, registry, out-
come, ClinESSDAI, ESSDAI
Introduction
Primary Sjögren’s syndrome (pSS) is an autoimmune
rheumatic disease characterised by inflammation of the ex-
ocrine glands, inducing a reduction in tear and salivary
production. The clinical presentation varies, ranging from
sicca symptoms associated with fatigue and arthralgia to
systemic extraglandular manifestations [1]. There is no de-
finitive treatment for pSS, but several clinical trials with
biological therapies are ongoing or planned [2–5].
In order to assess systemic disease activity in pSS, the EU-
LAR Sjögren’s Syndrome Disease Activity Index (ESS-
DAI) has been developed. This index consists of 12 do-
mains, 11 related to organ involvement and one biological
domain reflecting B-cell activity [6]. The levels of activity
of each domain (ranging from 0 to 3 points) are multiplied
by their respective weights (ranging from 1 to 7 points)
to obtain the total score. A user guide has been published
to help clinicians who use this tool [7]. ESSDAI has been
shown to be reliable and sensitive to change [8–10]. Cut-
off values of ESSDAI defining moderate (>5 and <14) and
severe (>14) systemic disease activity and the reduction in
the score that represents the minimal clinically important
improvement (MCII) have been proposed [11].
There is an issue when using the biological domain of the
ESSDAI in studies aimed at finding new biomarkers for
pSS or in clinical trials investigating drugs targeting B-
cell activity. This domain comprises hypergammaglobuli-
naemia, raised IgG or low complement levels and/or cryo-
globulinaemia. There is a risk of false positive associations
between a potential new biomarker and systemic disease
activity assessment because biomarkers are often correlat-
ed to B-cell activity, as is the biological domain of ESS-
DAI, producing a risk of multicollinearity of the data. In
other words, there is a rationale for an index detecting
clinical changes independently of the biological effects of
studied drugs in clinical trials. Such an index would also
be useful in monitoring clinical systemic disease activity,
without the need for immunological tests, in routine clini-
cal practice.
Therefore, the Clinical EULAR Sjögren’s Syndrome Dis-
ease Activity Index (ClinESSDAI) score has recently been
developed. ClinESSDAI includes the same domains as the
ESSDAI score apart from the biological domain. The
weightings of the remaining domains have been recalculat-
ed. This score has been validated through the same process
used for the ESSDAI with the same data set. The reliability
and sensitivity to change of ClinESSDAI are similar to
those of ESSDAI. The same cut-off values for levels of
disease activity (≥5 moderate activity, ≥14 high activity)
and MCII (3 points improvement) as for ESSDAI have
been validated [12]. Levels of activity for each domain and
their respective weights are summarised in table 1.
The UK Primary Sjögren’s Syndrome Registry (UKPSSR)
is a cohort of patients in the UK who fulfil the American-
European Consensus Group (AECG) classification criteria
for pSS, and are included in a research database and a tis-
sue bank [13, 14]. A previous paper discussed the eligibil-
ity of the UKPSSR cohort for clinical trials according to
different criteria, including the ESSDAI [15].
The American College of Rheumatology / European
League Against Rheumatism classification criteria (ACR-
EULAR) for pSS were published in 2016 and will proba-
Table 1: Levels of activity and respective weights of indexes domains and theoretical illustration of disease activity indexes ability to improve according to selected MCII values.
Does a one grade improvement in one domain permit reaching the MCII when using ESSDAI or ClinESSDAI for selected MCII values?
ESSDAI ClinESSDAI
MCII Weight MCII
Disease activity score domains Levels of activity
Weight
3 4 5 3 4 5
Constitutional 0–2 3 Yes No No 4 Yes Yes No
Lymphadenopathy 0–3 4 Yes Yes No 4 Yes Yes No
Glandular 0–2 2 No No No 2 No No No
Articular 0–3 2 No No No 3 Yes No No
Cutaneous 0–3 3 Yes No No 3 Yes No No
Pulmonary 0–3 5 Yes Yes Yes 6 Yes Yes Yes
Renal 0–3 5 Yes Yes Yes 6 Yes Yes Yes
Muscular 0–3 6 Yes Yes Yes 7 Yes Yes Yes
Peripheral nervous system 0–3 5 Yes Yes Yes 5 Yes Yes Yes
Central nervous system 0, 1, 3* 5 Yes Yes Yes 5 Yes Yes Yes
Haematological 0–3 2 No No No 2 No No No
Biological 0–2 1 No No No NR NR NR NR
ClinESSDAI = Clinical Sjögren’s Syndrome Disease Activity Index; ESSDAI = EULAR Sjögren’s Syndrome Disease Activity Index; MCII = minimal clinically important improve-
ment, NR = not relevant *A level of activity of 2 is not allowed for this domain.
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bly supersede the AECG criteria in defining inclusion cri-
teria in future clinical trials [16].
The objective of this study was to assess the impact of
using ClinESSDAI, in comparison with ESSDAI, in the
UKPSSR on the assessment of potential eligibility and the
ability to demonstrate change with treatment for future
controlled clinical trials in participants with pSS according
to the ACR-EULAR criteria.
Methods
Patients were recruited to the UKPSSR from August 2009.
Data used for analysis were extracted from the database
registry on 24 June 2013. All participants provided written
informed consent to be included in the UKPSSR. Research
ethical approval for the UKPSSR was obtained from Na-
tional Research Ethics Committee North West Haydock.
We selected for the primary analysis only participants ful-
filling the ACR-EULAR classification criteria (n = 665).
In a secondary analysis, we repeated the analysis with all
the participants included in the dataset who all fulfilled the
AECG classification criteria at inclusion or prior to inclu-
sion in the UKPSSR (n = 668).
In ESSDAI and ClinESSDAI, we arbitrarily divided the
domains into two groups. The first, defined as “major sys-
temic” domains, were those whose weightings in the index
calculation are 5 or more, and comprised the respiratory,
muscular, peripheral nervous system and central nervous
system and renal domains. We arbitrarily defined the sec-
ond group of domains as “general’ domains, comprising
constitutional, lymphadenopathy, glandular, articular, cuta-
neous, haematological and biological domains. This divi-
sion was based on a subjective view that the major sys-
temic domains, although clinically very important, are in-
dividually relatively rare and most are difficult to measure
objectively in a clinical trial context. As a consequence, the
more common general domains are likely to be of greater
use in evaluating the benefit of novel therapies in con-
trolled clinical trials in pSS.
The ClinESSDAI was calculated for every participant. We
analysed the distribution of ESSDAI and ClinESSDAI val-
ues. The distribution of active domains and their grading
were compared between ESSDAI and ClinESSDAI for
several cut-off indexes values: ≥5 (moderate systemic dis-
ease activity), ≥6, ≥7, >14 (high systemic disease activity).
We analysed the level of agreement between total ESSDAI
and ClinESSDAI scores. We also did a correlation analysis
between individual domains of both indexes.
In an exploratory analysis, we evaluated how the partici-
pants were able to reach the MCII, when this was set at
different values (3, 4 or 5). More specifically, we assessed
how many of them needed a one grade improvement in
one, two or three of their active domains to reach the MCII
value. We did the calculation for three cut-off values for
ESSDAI and ClinESSDAI (≥5, ≥6, ≥7).
Statistical analysis
Data were analysed with Microsoft Excel for descriptive
statistics and GraphPad Prism v7.01 for comparative
analyses. We used the chi2 test to compare discontinuous
variables between groups. We analysed the level of agree-
ment between total ESSDAI and ClinESSDAI scores using
the method described by Bland and Altman [17]. Differ-
ences between ESSDAI and ClinESSDAI were calculat-
ed for each patient and plotted against their average. The
standard deviation (SD) of such differences was calculat-
ed to estimate the limits of agreement. Spearman’s test was
used for correlations analyses. A p-value <0.05 was con-
sidered statistically significant. We generally made no cor-
rections for multiple comparisons as the analyses included
few comparisons, except for the correlation analyses be-
tween domains. As these analyses included many compar-
isons we made a Bonferroni correction and calculated a p-
value of 0.0009 for ClinESSDAI and 0.0007 ESSDAI to
be statistically significant.
Results
Eligibility for clinical trials
The number of patients potentially eligible for inclusion in
a clinical trial according to various disease activity index
cut-off values (≥5, ≥6, ≥7, ≥14) for ESSDAI and ClinESS-
DAI are reported in fig. 1. For each selected cut-off val-
ue, there were more patients available for potential trial
inclusion when ClinESSDAI was used than with use of
ESSDAI. For example, with a score ≥5 (the value defin-
ing moderate disease activity), 278 patients were eligible
(41.8%) with ESSDAI and 288 (43.3%) with ClinESSDAI;
with a score ≥14 (the value defining high disease activity),
36 patients were eligible (5.4%) with ESSDAI and 45
(6.8%) with ClinESSDAI.
Index values and domain activity distribution
In the analysed data from UKPSSR, the ESSDAI mean
value was 4.9 (SD 5.0, median 4.0, interquartile range
[IQR] 1.0–7.0) and the ClinESSDAI mean value was 4.9
(SD 5.6, median 4.0, IQR 0–7.0). The detailed score distri-
bution of ESSDAI and ClinESSDAI can be found in table
2. The distribution of patients according to defined activity
levels did not differ statistically (chi2 p = 0.57) when calcu-
lated with ESSDAI (moderate activity 36.4%, high activity
5.4%) or with ClinESSDAI (moderate activity 36.5%, high
activity 6.8%). Interestingly, there were 101 more patients
with an index value of 0 when ClinESSDAI was used in-
stead of ESSDAI. These patients had only one active do-
main, which was the biological domain with a level of ac-
tivity of 1 (n = 58) or 2 (n = 43).
When the frequency of active domains in patients with an
ESSDAI or ClinESSDAI score of ≥5, ≥6 or ≥7 were com-
pared, the only statistically significant difference was the
Figure 1: Participants distribution from the database according to
the calculated disease activity score (ESSDAI or ClinESSDAI).Cli-
nESSDAI = Clinical EULAR Sjögren's Syndrome Disease Activity
Index; ESSDAI = EULAR Sjögren's Syndrome Disease Activity In-
dex
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proportion of participants with an active articular domain
and an ESSDAI ≥7 or ClinESSDAI ≥7 (53 and 41%, re-
spectively; chi2 = 5.36, p = 0.02). The distribution of do-
main activity levels for participants with a ClinESSDAI
≥5, currently the cut-off value most used for inclusion in
clinical trials, can be found in figure 2.
Levels of agreement and correlation analysis
Figure 3 shows the differences between ESSDAI and Cli-
nESSDAI plotted against their average. The mean differ-
ence between the two indexes was −0.07. The SD of the
differences was 1.3. This value allows calculation of the
lower and upper levels of agreement between both index-
es, which are −2.5 and 2.4, respectively. The difference be-
tween both indexes was outside the levels of agreement for
22 (3.3%) patients, with a maximum difference value of 5.
In these cases, ClinESSDAI was always higher than ESS-
DAI, with values ranging from 10 to 43.
We observed statistically significant correlations between
domains when using ESSDAI or ClinESSDAI in the
UKPSSR data, summarised for patients with activity index
value ≥5 in table 3. The highest positive correlation coeffi-
cient was between the glandular and lymphadenopathy do-
mains for ESSDAI and ClinESSDAI for different index-
es cut-off values (all participants: rho = 0.196, p <0.0001
for both indexes; index ≥5: rho = 0.218, p = 0.0002, rho =
0.247, p <0.0001; index ≥6: rho = 0.263, p <0.0001, rho =
0.299, p <0.0001; index ≥7: rho = 0.313, p <0.0001, rho =
0.309, p <0.0001, for ESSDAI and ClinESSDAI, respec-
tively, using Spearman’s correlation).
Ability to improve by the minimal clinically important
improvement value
An MCII value of 3 has been recommended by the EU-
LAR group who developed the ESSDAI and ClinESSDAI,
although higher values could be chosen depending on the
clinical trial and eligibility criteria [11]. The number of
participants requiring a one grade improvement in one, two
or three of their active domains in order to reach several
MCII target values and disease activity index values are re-
ported in table 4. To help the reader to understand the rea-
soning, a theoretical illustration of the ability for individ-
ual domains alone to reach certain specified MCII target
values can be found in table 1. We observed that when an
MCII value of 3 or 4 was chosen, the proportion of patients
who need an improvement of only one grade in a single
domain to reach the MCII is higher when ClinESSDAI is
used instead of ESSDAI: 90.3/99.3, 92.9/99.2, 96.9/100%
(MCII = 3); 49.3/73.3, 54.9/80.5, 60.3/88.9% (MCII = 4)
for ESSDAI/ClinESSDAI ≥5, ≥ 6, ≥7, respectively.
Discussion
We evaluated the ClinESSDAI in comparison with ESS-
DAI in terms of theoretical patient recruitment and out-
Table 4: Ability to improve: number of participants from the UKPSSR requiring a one grade improvement in 1, 2, or 3 of their active domains to reach the MCII value according
to several MCII target values and disease activity scores.
Participant distributions according to the number of domains needing a one-
grade improvement to reach the selected MCII, n (%)
Egibility criteria
(disease activity
score)
Response criteria
(MCII)
Disease activity score
selected for calculation
Total of pa-
tients fulfilling
activity index
score
1 2 3 MCII not reach-
able
ESSDAI 278 251 (90.3) 27 (9.7) 0 0MCII = 3
ClinESSDAI 288 286 (99.3) 2 (0.7) 0 0
ESSDAI 278 137 (49.3) 113 (40.6) 15 (5.4) 13 (4.7)MCII = 4
ClinESSDAI 288 211 (73.3) 51 (17.7) 0 26 (9.0)
ESSDAI 278 110 (39.6) 119 (42.8) 17 (6.1) 32 (11.5)
≥5
MCII = 5
ClinESSDAI 288 110 (38.2) 145 (50.3) 0 33 (11.5)
ESSDAI 226 210 (92.9) 16 (7.1) 0 0MCII = 3
ClinESSDAI 257 255 (99.2) 2 (0.8) 0 0
ESSDAI 226 124 (54.9) 85 (37.6) 8 (3.5) 9 (4.0)MCII = 4
ClinESSDAI 257 207 (80.5) 24 (9.3) 0 26 (10.1)
ESSDAI 226 100 (44.2) 92 (40.7) 10 (4.4) 24 (10.6)
≥6
MCII = 5
ClinESSDAI 257 106 (41.2) 118 (45.9) 0 33 (12.8)
ESSDAI 194 188 (96.9) 6 (3.1) 0 0MCII = 3
ClinESSDAI 198 198 (100) 0 0 0
ESSDAI 194 117 (60.3) 74 (38.1) 3 (1.5) 0MCII = 4
ClinESSDAI 198 176 (88.9) 21 (10.6) 0 1 (0.5)
ESSDAI 194 96 (49.5) 79 (40.7) 5 (2.6) 14 (7.2)
≥7
MCII = 5
ClinESSDAI 198 93 (47.0) 99 (50.0) 0 6 (3.0)
ClinESSDAI = Clinical EULAR Sjögren’s Syndrome Disease Activity Index; ESSDAI = EULAR Sjögren’s Syndrome Disease Activity Index; MCII = minimal clinically important
improvement
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come measurement in clinical trials using the UKPSSR
dataset in participants fulfilling ACR-EULAR classifica-
tion criteria, which are likely to be used as inclusion crite-
ria for future trials.
Use of ClinESSDAI potentially modestly increases the
number of eligible participants for a clinical trial for any
selected index cut-off value.
Participants whose only active domain is the biological do-
main are attributed an index value of 0 in the ClinESSDAI,
as this domain in not part of this activity index. Therefore,
the proportion of participants with an index value of 0 is
higher with ClinESSDAI than with ESSDAI.
We found good agreement between ClinESSDAI and ESS-
DAI, with a mean difference between them close to zero
and limits of agreement smaller than the MCII of 3. How-
ever, we observed that ClinESSDAI tends to be higher than
ESSDAI (maximum difference 5) in some patients with a
total score of 10 or more and in all patients with a score
Table 2: Distribution of participants from the UKPSSR according to
disease activity score, calculated with ESSDAI or ClinESSDAI, total n
= 665.
Number of participants (%)Disease ac-
tivity index
values
ESSDAI ClinESSDAI
0 113 (17.0) 214 (32.2)
1 58 (8.7) 0
2 102 (15.3) 61 (9.2)
3 59 (8.9) 56 (8.4)
4 55 (8.3) 46 (6.9)
5 52 (7.8) 31 (4.7)
6 32 (4.8) 59 (8.9)
7 43 (6.5) 34 (5.1)
8 32 (4.8) 25 (3.8)
9 21 (3.2) 31 (4.7)
10 17 (2.6) 23 (3.5)
11 18 (2.7) 9 (1.4)
12 14 (2.1) 16 (2.4)
13 13 (2.0) 15 (2.3)
14 7 (1.1) 7 (1.1)
15 7 (1.1) 11 (1.7)
16 5 (0.8) 3 (0.5)
17 1 (0.2) 3 (0.5)
18 1 (0.2) 2 (0.3)
19 2 (0.3) 4 (0.6)
20 3 (0.5) 2 (0.3)
≥21 10 (1.5) 13 (2.0)
ClinESSDAI = Clinical EULAR Sjögren’s Syndrome Disease Activity In-
dex; ESSDAI = EULAR Sjögren’s Syndrome Disease Activity Index
Figure 2: Distribution of domain activity levels in participants with
a ClinESSDAI ≥5, n = 288.ClinESSDAI = Clinical EULAR Sjögren's
Syndrome Disease Activity Index.
of more than 25. Thus, caution is advised when using Cli-
nESSDAI in patients with high disease activity; however,
this affects only a small proportion of potentially eligible
participants in a clinical trial.
We found a consistent positive correlation between the
lymphadenopathy and glandular domains, and an inverse
correlation between the constitutional and respiratory/cu-
taneous domains, when using either ESSDAI or ClinESS-
DAI at different cut-off values. This could suggest the ex-
istence of subgroups of patients with different clinical pre-
sentations, eventually related to various underlying patho-
Figure 3: Differences between ESSDAI and ClinESSDAI plotted
against their averages (n = 665).ClinESSDAI = Clinical EULAR
Sjögren's Syndrome Disease Activity Index; ESSDAI = EULAR
Sjögren's Syndrome Disease Activity Index
Table 3: Correlation coefficients with p<0.05 between domains in par-
ticipants in the UKPSSR with an ESSDAI (n = 278) or ClinESSDAI (n
= 288) score ≥5.
Domain Rho p-value
ESSDAI ≥5 (n = 278)
Lymphadenopathy Glandular 0.22 0.0002*
Biological Haematological 0.19 0.002
Biological Cutaneous 0.15 0.01
Haematological Renal 0.13 0.03
Biological Renal 0.13 0.03
Glandular PNS −0.12 0.04
Constitutional Biological −0.12 0.04
Glandular Respiratory −0.13 0.04
Articular Cutaneous −0.13 0.03
Articular Muscular −0.13 0.03
Cutaneous Respiratory −0.17 0.006
Constitutional Cutaneous −0.23 0.0001*
Constitutional Respiratory −0.23 <0.0001*
ClinESSDAI ≥5 (n = 288)
Lymphadenopathy Glandular 0.25 <0.0001*
Haematological Renal 0.13 0.03
Glandular PNS −0.13 0.03
Glandular Respiratory −0.13 0.03
Articular Respiratory −0.14 0.02
Articular Muscular −0.16 0.009
Cutaneous Respiratory −0.16 0.009
Articular Cutaneous −0.19 0.001
Constitutional Cutaneous −0.20 0.001
Constitutional Respiratory −0.20 0.001
ClinESSDAI = Clinical EULAR Sjögren’s Syndrome Disease Activity In-
dex; ESSDAI = EULAR Sjögren’s Syndrome Disease Activity Index;
PNS = peripheral nervous system * Statistically significant with Bonfer-
roni correction for multiple comparisons testing. Rho coefficient calcu-
lated with Spearman’s test.
Original article Swiss Med Wkly. 2018;148:w14588
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 8
genesis pathways. As the efficacy of studied medications
could differ in these patients, subgroup analysis could be
useful in future clinical trials to identify which patients
are more likely to respond to different treatments. In an
exploratory analysis, we did not find any relationship be-
tween the correlation coefficients and the participants’
characteristics (disease duration, age, anti-Ro/La positivi-
ty). Nevertheless, these preliminary results need to be con-
firmed in other cohorts and with longitudinal data.
We assessed how the ability to change is affected by the
use of ClinESSDAI. We focused the analysis on patients
with scores ≥5, as this cut-off value, defining moderate dis-
ease activity, is most often used in controlled studies. In
our data, the use of ClinESSDAI made the MCII general-
ly more easily reachable with a one grade improvement in
one or two domains than with the use of ESSDAI. These
findings can be interpreted in two ways: it could mean that
ClinESSDAI will allow a more sensitive analysis and per-
haps earlier detection of change in a drug trial or, converse-
ly, it could artificially magnify the improvement of “soft”
domains (e.g., articular domain with arthralgia) not neces-
sarily representative of the full clinical picture of pSS.
We attempted to evaluate whether “major systemic” and
“general” domains behave differently with the use of ESS-
DAI and ClinESSDAI. We believe that the activity level of
major systemic domains is more difficult to assess than that
of general domains. This difficulty is due to the frequent
need of complementary investigations, such as imaging or
nerve conduction studies, for diagnosis. These domains are
often not formally assessed at each follow-up visit in rou-
tine care. In addition, investigations such as nerve conduc-
tion studies have not been validated for use as outcome
tools in clinical trials. We found no significant differences
in major systemic domain activity levels with the use of
ESSDAI or ClinESSDAI. As major systemic domains are
weighted 5 or more in the calculation of the scores, an im-
provement in any of these domains allows MCII values of
3, 4 or 5 to be achieved with both ESSDAI and ClinESS-
DAI.
In order to assess the influence of classification criteria on
our results, we performed the same analyses including all
UKPSSR participants, who all fulfilled the AECG classi-
fication criteria at inclusion or prior to inclusion as this is
a mandatory criterion for inclusion in the registry. Among
the 668 participants, we found that only 3 could be clas-
sified as pSS according to AECG criteria but not to the
new ACR-EULAR criteria. These patients all showed pos-
itivity for anti-La (SSB) and not for anti-Ro (SSA), which
are no longer part of ACR-EULAR classification criteria
for pSS. Globally, the results are very similar and conclu-
sions are identical with both sets of classification criteria
(data not shown). However, the new ACR-EULAR crite-
ria introduce a pSS classification different from the AECG
criteria. A patient can be classified as pSS if there is a
clinical suspicion of pSS and one active ESSDAI domain
even without sicca symptoms. This alternative classifica-
tion pathway was not assessed in the present study as it is
not part of the AECG criteria, which were previously used
for inclusion in the registry. Nevertheless, in our experi-
ence, the number of participants potentially affected by this
alternative classification pathway is likely to be marginal
and would not alter the results.
This study is limited by the fact that only baseline data
were available for the analysis, with no follow-up data. In
the French ASSESS cohort, the most frequent changes at
follow-up were seen not only in the biological, articular,
haematological and glandular domains, but also in the pul-
monary domain [18]. Objective evaluation of this domain
may require formal pulmonary function tests. In an Italian
longitudinal study with a 12 months’ follow-up, there was
a tendency to improvement for the articular and cutaneous
domains [19]. Whereas patients included in the UKPSSR
are not necessarily representative of pSS patient popula-
tions from other countries, this cohort is representative of
potentially eligible patients for clinical trials in the UK.
In a context of clinical trials in pSS, ClinESSDAI would
probably be used in studies investigating biomarkers or
drugs targeting B-cell activity, in order to avoid the issue of
collinearity of data. However, ESSDAI could also still be
calculated, as biological domain items (immunoglobulins,
complement, cryoglobulin) would certainly be recorded as
part of the drug safety assessment.
In conclusion, our data suggest that the use of ClinESS-
DAI, a modification of ESSDAI without the biological do-
main, is practicable, does not lead to a loss of potentially
eligible patients for trials, and does not significantly alter
the ability to identify changes of the indexes. However,
more studies are needed, especially longitudinal data to
confirm that ClinESSDAI could be used as an endpoint for
clinical trials studying medications with a B-cell or other
systemic effect, or in routine care for monitoring disease
activity when immunological tests are not available.
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